Essential Partners
GILD icon

Essential Partners’s Gilead Sciences GILD Stock Holding History

Essential Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$100K Buy
673
+158
+31% +$22.2K 0.05% 422
2026
Q2 		$65.1K Hold
515
– – 0.03% 540
2026
Q1 		$71.8K Buy
515
+39
+8% +$5.46K 0.02% 498
2025
Q4 		$58.5K Buy
476
+19
+4% +$2.31K 0.02% 573
2025
Q3 		$50.8K Buy
457
+13
+3% +$1.48K 0.02% 591
2025
Q2 		$49.2K Buy
+444
New +$47.3K 0.02% 481

Other funds holding GILD

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Essential Partners's GILD Position: Q3 2026 in Review

Essential Partners increased its Gilead Sciences (GILD) stake by 31% in Q3 2026, buying an estimated $22.2K and bringing the position to 673 shares worth $100K. The position accounts for 0.05% of the portfolio, ranked #422.

Essential Partners first reported a position in GILD in Q2 2025 and has held it in 6 quarters since. 1,364 funds tracked by Wall St. Rank hold GILD as of Q3 2026.

  • Essential Partners held 673 shares of Gilead Sciences worth $100K as of Q3 2026.
  • Essential Partners bought 158 Gilead Sciences shares in Q3 2026, an estimated $22.2K.
  • Gilead Sciences made up 0.05% of Essential Partners's portfolio in Q3 2026, its #422 holding.
  • Essential Partners first reported a position in Gilead Sciences in Q2 2025 and has held it in 6 quarters since.
  • 1,364 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.